Viamet Pharmaceuticals, Inc., a world leader in the development of “best-in-class” therapies targeting key metalloenzymes, announced today the appointment of Richard D. Katz, M.D. to the newly-created position of Chief Business and Financial Officer
March 7, 2012
· 1 min read